Multiple large trials have shown that GLP 1 medications reduce the risk of major cardiovascular events, including heart attack and stroke
PwC's parallel analysis of Numerator transaction data puts roughly one in five U.S
Head-to-head comparison The right choice depends entirely on your situation
However, we welcome the governments new direction to prescribers that there is now sufficient stock of Rybelsus to allow new initiation of this medication and hope that many people with T2DM who could benefit will now be able to be initiated onto a GLP-1 for the first time
Finally, semaglutide has been associated with a lower incidence of gastrointestinal adverse events compared to other GLP-1 RAs, such as dulaglutide and liraglutide [46, 47]
Knowing your baseline B12 status before starting semaglutideand understanding how compound formulations address thisempowers you to work with your provider on a monitoring plan that fits your individual metabolism and risk profile
